Comparison of cetuximab every 2 weeks versus standard once-weekly administration for the first-line treatment of RAS wild-type metastatic colorectal cancer among patients with left- and right-sided primary tumor location

被引：0
|
作者：
Kasper, S. [1 ]
Cheng, A-L. [2 ]
Rouyer, M. [3 ]
Foch, C. [4 ]
Lamy, F-X. [5 ]
Esser, R. [6 ]
Batech, M. [7 ]
Wong, C. M. J. [8 ]
Zhang, A. [9 ]
Brodowicz, T. [10 ]
Zielinski, C. [11 ,12 ]
机构：
[1] Univ Hosp Essen Westdeutsches Tumorzentrum, Med Oncol Dept, Essen, Germany
[2] Natl Taiwan Univ, Canc Ctr, Dept Internal Med & Oncol, Taipei, Taiwan
[3] Univ Bordeaux, Bordeaux PharmacoEpi, Bordeaux, France
[4] Merck KGaA, R&D Global Biostat Epidemiol & Med Writing, Darmstadt, Germany
[5] Merck KGaA, Global Epidemiol Dept, Darmstadt, Germany
[6] Merck KGaA, Global Med Affairs, Darmstadt, Germany
[7] Merck KGaA, Med Oncol, Darmstadt, Germany
[8] Cytel Singapore Pte Ltd, Project Based Serv, Singapore, Singapore
[9] Merck Serono, R&D Global Biostat, Beijing, Peoples R China
[10] Med Univ Vienna, Gen Hosp, Internal Med 1, Dept Med Oncol, Vienna, Austria
[11] Vienna Gen Hosp, Comprehens Canc Ctr, Oncol, Vienna, Austria
[12] Med Univ Vienna, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.936
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
415P
引用
收藏
页码：S542 / S543
页数：2
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial
    Wang, Huijuan
    Huang, Lingfei
    Gao, Peng
    Zhu, Zhengyi
    Ye, Weifeng
    Ding, Haiying
    Fang, Luo
    BMJ OPEN, 2020, 10 (02):
  • [42] Cost-effectiveness of cetuximab plus FOLFIRI versus bevacizumab plus FOLFIRI in the first-line treatment of RAS wild-type metastatic colorectal cancer in China.
    Van Oostrum, Ilse
    Hu Yannan
    Yuan Zijiao
    Schlichting, Michael
    Tao Libo
    Pescott, Chris P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [43] Impact of primary tumor side (TS) on outcomes of once-every-2-weeks (q2w) cetuximab plus first-line (1L) FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.
    Price, Timothy Jay
    Shen, Lin
    Ma, Brigette
    Esser, Regina
    Chen, Wen-Feng
    Gibbs, Peter
    Lim, Robert S. C.
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [44] Cost-effectiveness analysis of selective first-line use of biologics for unresectable RAS wild-type left-sided metastatic colorectal cancer
    Wong, W. W. L.
    Zargar, M.
    Berry, S. R.
    Ko, Y. J.
    Riesco-Martinez, M.
    Chan, K. K. W.
    CURRENT ONCOLOGY, 2019, 26 (05) : E597 - E609
  • [45] First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy?
    Airoldi, Marco
    Bartolini, Michela
    Fazio, Roberta
    Farinatti, Sara
    Dapra, Valentina
    Santoro, Armando
    Puccini, Alberto
    CURRENT ONCOLOGY REPORTS, 2024, 26 (11) : 1489 - 1501
  • [46] Maintenance treatment with capecitabine plus cetuximab after first-line standard fluorouracil-based chemotherapy plus cetuximab for patients with RAS wild-type advanced colorectal cancer.
    Yuan, Xianglin
    Zhao, Ben
    Qiu, Hong
    Zhang, Mingsheng
    Zou, Yanmei
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [47] The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy
    Cai, Changjing
    Luo, Qingqing
    Liu, Yihan
    Peng, Yinghui
    Zhang, Xiangyang
    Jiang, Zhaohui
    Feng, Ziyang
    Qi, Yaru
    Gao, Yan
    Liu, Yongting
    Liu, Ping
    Chen, Yihong
    Guo, Cao
    Shen, Hong
    Zeng, Shan
    Han, Ying
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [48] A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF PANITUMUMAB WITH CHEMOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH WILD-TYPE RAS METASTATIC COLORECTAL CANCER (MCRC) WITH LEFT-SIDED TUMORS
    Zhou, A.
    Cameron, C.
    Mak, D.
    VALUE IN HEALTH, 2018, 21 : S18 - S18
  • [49] FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study
    Brodowicz, T.
    Ciuleanu, T. E.
    Radosavljevic, D.
    Shacham-Shmueli, E.
    Vrbanec, D.
    Plate, S.
    Mrsic-Krmpotic, Z.
    Dank, M.
    Purkalne, G.
    Messinger, D.
    Zielinski, C. C.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1769 - 1777
  • [50] Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
    Ciuleanu, T.
    Nikolic, V.
    Shmueli, E.
    Vrbanec, D.
    Plate, S.
    Krmpotic, Z. M.
    Dank, M.
    Purkaine, G.
    Brodowicz, T.
    Zielinski, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345